P/E ratio for Monopar Therapeutics (MNPR)
P/E ratio as of May 2024 (TTM): -0.8019
According to Monopar Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.801948. At the end of 2022 the company had a P/E ratio of -2.86.
P/E ratio history for Monopar Therapeutics from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.86 | -34.17% |
| 2021 | -4.34 | -58.89% |
| 2020 | -10.6 | -74.35% |
| 2019 | -41.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.14 | 415.94% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.